Prime Medicine Inc (PRME)

Currency in USD
3.810
+0.350(+10.12%)
Closed·
3.8100.000(-0.01%)
·
PRME Scorecard
Full Analysis
8 analysts have revised their earnings upwards for the upcoming period
PRME is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
3.4703.880
52 wk Range
1.1105.170
Key Statistics
Prev. Close
3.81
Open
3.5
Day's Range
3.47-3.88
52 wk Range
1.11-5.17
Volume
3.19M
Average Volume (3m)
4.22M
1-Year Change
-11.19%
Book Value / Share
0.48
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
PRME Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
7.125
Upside
+87.01%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Prime Medicine Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy

Prime Medicine Inc Company Profile

Prime Medicine, Inc., a biotechnology company, engages in delivering genetic therapies to address the spectrum of diseases by deploying gene editing technology in the United States. It offers Prime Editing technology comprising a programmable DNA binding domains, such as Cas domains, are typically modified such that they do not cause a double-stranded break in the DNA, as well as a RT domain that copies the edited DNA sequence directly into the target genomic site where the edit is made; and pegRNA which contains a search sequence, also known as a spacer, which provides a target genomic address for the Prime Editor. The company has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. Prime Medicine, Inc. was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.

Compare PRME to Peers and Sector

Metrics to compare
PRME
Peers
Sector
Relationship
P/E Ratio
−2.5x−1.7x−0.5x
PEG Ratio
−0.09−0.020.00
Price/Book
8.2x1.0x2.6x
Price / LTM Sales
100.7x44.4x3.3x
Upside (Analyst Target)
57.5%272.2%40.3%
Fair Value Upside
Unlock16.8%4.7%Unlock

Analyst Ratings

8 Buy
4 Hold
0 Sell
Ratings:
12 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 7.125
(+87.01% Upside)

Earnings

Latest Release
Aug 07, 2025
EPS / Forecast
-0.41 / -0.43
Revenue / Forecast
1.11M / --
EPS Revisions
Last 90 days

PRME Income Statement

People Also Watch

43.000
RKLB
-0.99%
50.050
ASTS
+0.58%
193.64
ALAB
+0.85%
61.63
BMNR
-1.30%
6.3400
EOSE
+3.76%

FAQ

What Stock Exchange Does Prime Medicine Trade On?

Prime Medicine is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Prime Medicine?

The stock symbol for Prime Medicine is "PRME."

What Is the Prime Medicine Market Cap?

As of today, Prime Medicine market cap is 499.50M.

What Is Prime Medicine's Earnings Per Share (TTM)?

The Prime Medicine EPS (TTM) is -1.57.

When Is the Next Prime Medicine Earnings Date?

Prime Medicine will release its next earnings report on 30 Oct 2025.

From a Technical Analysis Perspective, Is PRME a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has Prime Medicine Stock Split?

Prime Medicine has split 0 times.

How Many Employees Does Prime Medicine Have?

Prime Medicine has 214 employees.

What is the current trading status of Prime Medicine (PRME)?

As of 14 Aug 2025, Prime Medicine (PRME) is trading at a price of 3.81, with a previous close of 3.81. The stock has fluctuated within a day range of 3.47 to 3.88, while its 52-week range spans from 1.11 to 5.17.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.